On July 10, 2023, SpyGlass Pharma, a privately-held ophthalmic therapeutics company, announced the closing of $90 million in Series C financing. The financing, which was led by RA Capital Management alongside existing investors New Enterprise Associates and Vensana Capital, as well as new investors Samsara BioCapital and Vertex Ventures HC, will enable the company to conduct multiple U.S. clinical trials of SpyGlass’ innovative drug delivery platform. The SpyGlass system has the potential to deliver multiple years of medical therapy to address significant unmet needs in glaucoma management as well as other chronic ophthalmic diseases, when implanted at the time of routine cataract surgery.

Wilson Sonsini Goodrich & Rosati represented SpyGlass in the transaction. The team was led by Dan Koeppen, Kassandra Castillo, and Bridget Balisy.

For more information, please see SpyGlass's press release.